Epilepsy Intractable Clinical Trial
Official title:
Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs
Verified date | July 2019 |
Source | Brain Sentinel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label, randomized, prospective study of the impact on healthcare utilization of a surface Electromyography (sEMG) based seizure monitoring and alerting system for Veterans with seizures with upper extremity motor involvement, that are refractory to three or more antiepileptic drugs.
Status | Not yet recruiting |
Enrollment | 58 |
Est. completion date | January 2026 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility |
Inclusion Criteria: 1. Subject is a veteran with a reported history of motor seizures (epileptic, non-epileptic or unknown) with upper extremity motor involvement, presenting with questionable spell characterization. 2. Subjects suspected of experiencing one or more spells per month. 3. Subjects has failed at least 3 anti-epileptic drugs (single or combination). 4. Male or Female between the ages 22 to 99. 5. If female and of childbearing potential, subject must agree to not become pregnant during the trial. 6. Can understand and sign written informed consent or will have a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments. 7. Subject or Primary Caregiver must be competent to follow all study procedures. 8. Subject must be willing to use the Seizure Monitoring and Alerting System for a prolonged period (up to five months), for a minimum of 30 hours/ week. Exclusion Criteria: 1. The subject cannot be pregnant, or nursing. 2. The subject cannot be sensitive or allergic to adhesives or tapes. 3. The subject may not be enrolled in another Clinical Trial. 4. The subject is homeless or in a home without a power supply. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Brain Sentinel |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic Impact Form Questionnaire | The physician will complete this questionnaire after each 30 days of device use to determine if information acquired will change the physician's assessment of the patient's seizures and their treatment plan. | Up to 5 months | |
Secondary | Personal Impact of Epilepsy Scale (PIES) Survey | The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy. | 1 year | |
Secondary | VR-12 Survey | This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY). | 1 year | |
Secondary | Personal Impact of Epilepsy Scale (PIES) Survey | The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy. | 5 years | |
Secondary | VR-12 Survey | This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY). | 5 years | |
Secondary | VA Administrative Data | Healthcare utilization, medication, and cost data will be collected to determine VA administrative data will be used to evaluate health outcomes. | 1 year | |
Secondary | VA Administrative Data | VA administrative data will be used to evaluate health outcomes. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03014752 -
Comparison of the Effectiveness of the Outpatient Classical Ketogenic Diet and Modified Atkins Diet on Seizures Frequency, Nutritional Status and Some Biochemical Factors in Children and Adolescents With Intractable Epilepsy
|
Phase 2/Phase 3 | |
Terminated |
NCT03790436 -
Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet
|
N/A | |
Completed |
NCT05503511 -
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT04286776 -
Memory Retrieval and Encoding Investigated by Neural Stimulation
|
N/A | |
Completed |
NCT04763070 -
Ciprofloxacin in Drug-resistant Epilepsy
|
N/A | |
Completed |
NCT03403907 -
The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients
|
N/A | |
Recruiting |
NCT04158531 -
REC2Stim as a Treatment for Refractory Epilepsy in the Primary Sensorimotor Cortex.
|
N/A | |
Recruiting |
NCT03289572 -
Microgrid II - Electrocorticography Signals for Human Hand Prosthetics
|
||
Enrolling by invitation |
NCT05332990 -
Multicenter Comparison of Interictal HFO as a Predictor of Seizure Freedom
|
||
Recruiting |
NCT04325360 -
Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory Epilepsy
|
N/A | |
Active, not recruiting |
NCT05727943 -
Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study
|
Phase 2 | |
Recruiting |
NCT04649008 -
Localizing Epileptic Networks Using MRI and iEEG
|
Early Phase 1 | |
Active, not recruiting |
NCT03916848 -
Novel Network Analysis of Intracranial Stereoelectroencephalography
|
N/A | |
Completed |
NCT03646240 -
ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
|
Phase 1 | |
Recruiting |
NCT03857074 -
Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy
|
N/A | |
Enrolling by invitation |
NCT03702127 -
TMS - Intracranial Electrodes
|
N/A | |
Recruiting |
NCT05015868 -
Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies
|
N/A | |
Enrolling by invitation |
NCT06138808 -
5-SENSE Score Validation Study
|
||
Enrolling by invitation |
NCT05248269 -
Thermocoagulation in Drug Resistant Focal Epilepsy
|
N/A | |
Completed |
NCT04399954 -
Evaluation of Ketoflo
|
N/A |